NCT07530770

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Effectiveness and Safety of Benralizumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Detailed description

Subjects who have been identified to have severe asthma with ABPA will be consented and enrolled in the study to receive benralizumab injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment with a follow-up/termination visit eight weeks from the last injection. The termination visit will occur week 24 for subjects who complete the study treatment. Subjects who receive the first dose of benralizumab but withdraw from the study or terminate study treatment for any reason should complete all the procedures outlined for the termination visit.

Conditions

• Allergic Bronchopulmonary Aspergillosis
• Severe Asthma
• ABPA

Interventions

Type	Name	Description
DRUG	Fasenra	30 Mg/mL Subcutaneous Solution

Timeline

• Start date: 2025-09-01
• Primary completion: 2026-07-31
• Completion: 2026-12-01
• First posted: 2026-04-15
• Last updated: 2026-04-15

Locations

2 sites across 1 country: China

Regulatory

• FDA-regulated drug study